# Pharmaceutical Giants Prioritize AI Partnerships and Licensing Over Corporate Buyouts

- URL: https://stocks.freetheai.org/news/pharmaceutical-giants-prioritize-ai-partnerships-and-licensing-over-corporate-07b8ed
- Published: 2026-10-16T23:57:18Z
- Category: company_news; sentiment: neutral; impact: medium
- Symbols: [NASDAQ:GILD](https://stocks.freetheai.org/symbols/NASDAQ-GILD), [LSE:AZN](https://stocks.freetheai.org/symbols/LSE-AZN), [BX:RHO](https://stocks.freetheai.org/symbols/BX-RHO)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Major pharmaceutical companies pivoted away from large corporate acquisitions this week, choosing instead to secure research partnerships and technology licenses. Gilead Sciences, Inc. (GILD), AstraZeneca PLC (AZN), and Roche Holding Ltd (RHO) struck agreements to access artificial intelligence platforms and novel drug candidates targeting oncology and metabolic diseases. Gilead partnered with Vir Biotechnology (VIR) on cancer drugs in a deal worth up to $1.74 billion in milestone payments, while AstraZeneca teamed up with insitro on a MASH research deal with $40 million upfront and up to $1.46 billion in potential milestones.

The strategy reflects an industry focus on addressing specific biological gaps rather than buying entire companies. Obesity and cancer remain central priorities. Roche secured rights to a fat-tissue candidate from Rona Therapeutics designed to reduce visceral fat while preserving muscle mass, committing up to $100 million upfront. Zealand Pharma partnered with Generate Biomedicines (GENB) on AI-designed obesity drugs in a deal with nearly $1.2 billion in potential milestones, and Pfizer Inc. (PFE) inked a deal exceeding $500 million with Enodia Therapeutics.

Investors will watch how effectively these drug discovery platforms move into clinical trials. For Gilead and AstraZeneca, future growth depends on converting early research into viable therapies, as both lead late-stage testing and commercial distribution. Broad market interest in biotech has moderated recently, with key sector funds showing short-term pullbacks despite solid gains for the year.

## Key points

- Gilead Sciences (GILD) partnered with Vir Biotechnology (VIR) on cancer therapies in a deal with $90 million upfront and up to $1.74 billion in milestones.
- AstraZeneca PLC (AZN) signed an AI collaboration with insitro for MASH treatments, providing $40 million upfront and up to $1.46 billion in milestones.
- Roche Holding Ltd (RHO) licensed an obesity drug candidate from Rona Therapeutics targeting visceral fat while preserving lean muscle mass.
- Zealand Pharma and Generate Biomedicines (GENB) partnered on AI-designed obesity treatments in a deal worth up to $1.2 billion in milestones.

## Questions and answers

### Why are major drugmakers choosing pipeline deals over full company acquisitions?

Big pharmaceutical firms are securing targeted research tools and early-stage candidates to address specific biological gaps in cancer and obesity, avoiding the high cost and complexity of acquiring full companies or existing approved drugs.

### What are the terms of the cancer drug partnership between Gilead and Vir Biotechnology?

Gilead Sciences partnered with Vir Biotechnology to discover solid tumor candidates. Vir receives $90 million upfront, up to $45 million in preclinical milestones, and up to $1.74 billion in future development, regulatory, and commercial milestone payments.

### How does Roche's licensed obesity candidate differ from traditional GLP-1 drugs?

Roche licensed a candidate from Rona Therapeutics that targets a protein expressed in fat tissues to selectively lower visceral fat while preserving lean muscle mass, serving as a complement to standard GLP-1 therapies.